Chronic nicotine treatment elicits a brain region-selective increase in the number of high-affinity agonist binding sites, a phenomenon termed up-regulation. Nicotine-induced up-regulation of ␣4␤2-nicotinic acetylcholine receptors (nAChRs) in cell cultures results from increased assembly and/or decreased degradation of nAChRs, leading to increased nAChR protein levels. To evaluate whether the increased binding in mouse brain results from an increase in nAChR subunit proteins, C57BL/6 mice were treated with nicotine by chronic intravenous infusion. 125 I]A85380, perhaps because the small ligand penetrated deeply into the sections, whereas the much larger mAbs encountered permeability barriers. Immunoprecipitation of [
Introduction
Chronic nicotine exposure elicits increases in high-affinity nicotinic receptor (nAChR) binding sites (termed up-regulation) in the brains of mice (Marks et al., 1983 (Marks et al., , 2004 , rats Kellar, 1983, 1985; Flores et al., 1992; Perry et al., 2007; Moretti et al., 2010) , and humans (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999) . Immunoprecipitation of the binding sites after chronic nicotine treatment indicates that the ␣4␤2*-nAChR subtype accounts for most of the increased binding sites in rat brain (Flores et al., 1992) . Although chronic nicotine exposure generally increases the density of ␣4␤2*-nAChR sites in rodent brain, the extent of the increase varies among brain regions (Marks et al., 1983 (Marks et al., , 2004 Pauly et al., 1991; Sanderson et al., 1993; Rowell and Li, 1997; Nguyen et al., 2003) .
Early studies determined that chronic nicotine treatment elicits an increase in maximal ligand binding (B max ) with no change in affinity (K D ) (Marks et al., 1983; Schwartz and Kellar, 1983) , indicating that the increased binding resulted from an increase in nAChR protein. In cell cultures nicotine and other cholinergic ligands increase the assembly of nAChR subunits and decrease the turnover of mature nAChRs (Peng et al., 1994; Kuryatov et al., 2005; Sallette et al., 2005; Lester et al., 2009) . However, an alternative hypothesis is that the increase in binding sites reflects a change in affinity of nAChR allowing the measurement of previously undetectable binding sites (Vallejo et al., 2005) . This hypothesis predicts an increase in binding with little or no change in the amount of nAChR protein.
Immunochemical methods have been used to evaluate the effects of chronic nicotine treatment on ␣4␤2*-nAChR in brain and have established that the high affinity agonist binding sites that are increased by chronic nicotine treatment can be immunoprecipitated by antibodies to either the ␣4 or ␤2 subunit (Flores et al., 1992; Moretti et al., 2010) . While these studies clearly establish that the binding sites, including those up-regulated by chronic nicotine, are assembled from ␣4 and ␤2 nAChR subunits, they do not establish whether chronic nicotine actually increases the amount of nAChR protein.
Evidence that supports the argument that chronic nicotine treatment increases the amount of subunit protein has been obtained in a study that used mice engineered to express an ␣4 subunit tagged with a fluorescent reporter incorporated into the cytoplasmic domain (Nashmi et al., 2007) and in a study that used quantitative Western blots to measure ␣4␤2-nAChR subunit proteins in rat brain (Moretti et al., 2010) . However, it has been difficult to extend the immunochemical analyses to provide resolution at a microscopic level, owing in part to the difficulty in using anti-nAChR antibodies in standard immunocytochemical procedures (Jones and Wonnacott, 2005; Moser et al., 2007) . The use of 125 I-labeled monoclonal antibodies (mAbs) has overcome some of these difficulties for select nAChR subunits including ␤2 with [ 125 I]mAb 270 (Swanson et al., 1987; Whiteaker et al., 2006) and ␣4 with [
125 I]mAb 299 (Whiteaker et al., 2006) . We investigated the effect of chronic nicotine treatment on the expression of ␣4␤2*-nAChR using ligand binding with the ␤2-selective ligand [
125 I]A85380 (3-[(2S)-2-azetidinylmethoxy]-5-iodopyridine) (Mukhin et al., 2000) and immunolabeling of ␣4 subunits with [
125 I]mAb 299 and ␤2 subunits with [
125 I]mAb 270 (Whiteaker et al., 2006) . The results demonstrate a region-selective, nicotine-dose-dependent increase not only in nAChR binding but also in antibody labeling. These results strongly support the hypothesis that the increase in high-affinity nAChR binding sites results from increases in assembled nAChR subunit proteins.
Materials and Methods

Materials. [
125 I]epibatidine and [ 125 I]A85380 were obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA). NaCl, KCl, MgSO 4 , CaCl 2 , Na 2 HPO 4 , NaH 2 PO 4 , bovine serum albumin, polyethylene glycol (PEG), polyethylenimine, nicotine, and cytisine were obtained from Sigma-Aldrich (St. Louis, MO). Sucrose was obtained from Roche Diagnostics (Indianapolis, IN). HEPES and NaHEPES are products of BDH (Poole, Dorset, UK) and were obtained through VWR (West Chester, PA). Normal rat serum, protease-free bovine serum albumin, and rabbit anti-rat polyclonal antibody were obtained from Jackson ImmunoResearch Laboratories Inc. (West Grove PA). Glass filters type B were products of MicroFiltration Systems (Dublin, CA), and glass fiber filters type A/E were products of Pall Life Sciences (Port Washington, NY). Superfrost Plus microscope slides and silastic tubing (a product of Dow Corning, Midland, MI) were obtained from Thermo Fisher Scientific (Waltham, MA).
Mice. Animal production methods and experimental procedures using mice were reviewed and approved by the Animal Care and Utilization Committee at the University of Colorado, Boulder.
C57BL/6 mice were bred in the specific pathogen-free mouse colony at the Institute for Behavioral Genetics, University of Colorado, Boulder. Mice were weaned at 25 days of age and housed five per cage with like-sexed animals. ␤2 Null mutant mice (Picciotto et al., 1995) were originally obtained from Marina Picciotto (Yale University, New Haven, CT). Heterozygous mice were mated to yield wild type (ϩ/ϩ), heterozygous (ϩ/Ϫ), and homozygous (Ϫ/Ϫ) mutant mice. Genotypes were determined from tail clippings obtained from mice approximately 40 days old as described previously (Picciotto et al., 1995) . Mice were housed in a vivarium maintained at 22°C and allowed free access to food and water. Lights were on from 7 AM to 7 PM.
Surgery. A cannula constructed of silastic tubing was inserted in the right jugular vein of each mouse (Marks et al., 1983) . In brief, mice were anesthetized with pentobarbital (50 mg/kg) and chloral hydrate (100 mg/kg). An incision (approximately 1 cm) was made to expose the superficial right jugular vein. The silastic cannula (0.51 mm i.d., 0.94 mm o.d.) was inserted 8 mm into the right jugular vein through a small hole in the vein. The cannula, filled with isotonic saline containing 0.3% citric acid, was anchored to the underlying tissue with surgical thread, passed through the back in the midscapular region, and anchored to the skin with a wound clip. A head mount composed of dental cement, into which a small metal hook was inserted, was affixed to the skull. The mouse was injected with buprenorphine (0.1 mg/kg), placed in a clean cage, and warmed until wakening.
Nicotine Treatment. After recovery from surgery each mouse was transferred to an individual infusion chamber (15 ϫ 15 ϫ 25 cm, length ϫ width ϫ height), and its cannula was attached to medicalgrade Tygon tubing connected to a 1-ml syringe mounted on an infusion pump (Harvard Apparatus Inc., Holliston, MA). Sterile saline was continuously infused at a rate of 35 l/h. After 2 days of saline infusion, nicotine treatment was begun. Mice were divided into seven treatment groups that received the following nicotine doses: 0 (saline-infused control), 0.125, 0.25, 0.5, 1.0, 2.0, or 4.0 mg/kg/h. Nicotine solutions were prepared from liquid nicotine neutralized with HCl. All doses were free base. After 10 days of treatment with the indicated nicotine dose, the cannula of each mouse was disconnected from the Tygon tubing and checked for free fluid flow.
Tissue Preparation. A 2-h interval between discontinuation of nicotine treatment and sacrifice was used to allow nearly total metabolism of nicotine (Petersen et al., 1984) .
For samples to be prepared for sectioning, each mouse was killed by cervical dislocation, and its brain was rapidly (Ͻ1 min) removed from the skull and quickly frozen by immersion in isopentane (Ϫ35°C) for 10 s. The frozen brain was wrapped in aluminum foil and stored at Ϫ70°C until sectioning.
Preparation of Tissue Sections. On the day of sectioning a brain was removed from the Ϫ70°C freezer and allowed to warm to the temperature of the cryostat (Ϫ14°C). The brain was subsequently mounted on the cryostat chuck with M-1 Embedding Matrix (Anatomical Pathology, Pittsburgh, PA). Subsequently, coronal sections (14 m thick) were obtained using either a Leica CM 1850 cryostat/ microtome (Leica, Nussloch, Germany) or an IEC Minotome (Damon Corp., Needham, MA) and thaw-mounted on Fisher Suprafrost/Plus microscope slides. A series of 10 sets of sections was prepared from each brain to allow comparison of results for several different experiments on adjacent or near-adjacent sections. Slides containing the brain sections were stored, desiccated at Ϫ70°C, until use.
[ 125 I]A85380 Autoradiography. Slides containing the tissue sections prepared from mice of each nicotine treatment group were warmed to room temperature in a desiccator. Slides were subsequently transferred to Bel-Art slide racks that have been modified to hold 50 slides and rehydrated by incubation at 22°C for 15 min in isotonic buffer (144 mM NaCl, 2.2 mM KCl, 2.0 mM CaCl 2 , 1.0 mM MgSO 4 , 25 mM HEPES, pH 7.5). The racks containing the rehydrated slides were subsequently transferred to the isotonic buffer containing 200 pM I-A85380. [
125 I]A85380, specific activity 2200 Ci/mmol was mixed with unlabeled 5I-A85380 to yield a final specific activity of 220 Ci/mmol (a 10-fold dilution). Samples were incubated for 2 h at 22°C. After the incubation the slides were redistributed to slide racks containing 25 slides and washed as follows (all solutions at 4°C): twice for 30 s in isotonic buffer, twice for 5 s in hypotonic buffer (0.1ϫ), and twice for 5 s in 10 mM HEPES, pH 7.5. The samples were then air-dried with a stream of air and stored desiccated at room temperature in vacuum overnight before exposure initially to Packard Super Resolution Cyclone Storage Phosphor Screens (PerkinElmer Life and Analytical Sciences) to yield images for quantitation and subsequently to Kodak MR autoradiography film (Eastman Kodak, Rochester, NY) to yield higher resolution images for photography. Each Phosphor Screen was also simultaneously exposed to a series of tissue paste standards containing measured amounts of 125 I to allow quantitation of the image intensity. Tissue sections from ␤2 null mutant mice were used to establish blanks (Whiteaker et al., 2006 , which has been characterized as a ␤2 nAChR subunit-selective antibody (Conroy et al., 1992; Whiteaker et al., 2006) and mAb 299 , which has been characterized as an ␣4 nAChR-selective antibody (Whiteaker et al., 2006) , were radioiodinated by reaction of Na 125 I with each mAb using a modified chloramine T method (Lindstrom et al., 1981 Autoradiographic methods for 125 I-mAb binding were modified from the method of Swanson et al. (1987) as detailed previously (Whiteaker et al., 2006) and modified as follows. Slides containing the tissue sections prepared from mice of each nicotine treatment group were warmed to room temperature in a dessicator. Slides were subsequently transferred to Bel-Art slide racks modified to hold 50 slides and rehydrated by incubation at 22°C for 15 min in phosphatebuffered saline (PBS; 100 mM NaCl and 10 mM sodium phosphate buffer, pH 7.5) that included 10 M phenylmethylsulfonyl fluoride. After rehydration, the slides were transferred to PBS containing 10 mM NaN 3 , 10% (v/v) normal rat serum, and 5% (w/v) protease-free bovine serum albumin in addition to the radiolabeled mAbs. Final antibody concentrations were 0.7 nM for [ 125 I]mAb 270 and 0.3 nM for [
125 I]mAb 299. These concentrations are near the K D values for the mAbs and provide optimal signal-to-noise ratios (Whiteaker et al., 2006) . Trays containing the 50 slides were incubated for 48 h at 4°C in slide boxes containing 100 ml of mAb containing buffer so that incubation conditions were maintained as uniform as possible. After the 48-h incubation, slides were washed using four 30-min incubations with PBS at 22°C. The samples were then air-dried and stored desiccated at room temperature in vacuum overnight. Samples were initially exposed to Packard Super Resolution Cyclone Storage Phosphor Screens to yield images for quantitation. Each Phosphor Screen was also simultaneously exposed to a series of tissue paste standards containing measured amounts of 125 I to allow quantitation of the image intensity. Tissue sections from ␤2 null mutant mice were used to establish blanks.
Samples were subsequently exposed to Kodak MR autoradiography film to yield higher resolution images for photography.
Quantitation. Tissue paste samples prepared from whole brain homogenates were used to construct standard curves. The Phosphor Screens yielded a linear relationship between signal intensity and tissue radioactivity content over several orders of magnitude. The regression line calculated for the standard curve was used to convert the measured value of pixels/mm 2 to the cpm/mg wet weight. Signal intensity in fmol/mg wet weight was estimated from the specific activity of each ligand. Brain regions were identified using the mouse brain atlas (Franklin and Paxinos, 1997) 125 I]epibatidine, the binding of which is unaffected by Triton X-100 solubilization, was used to measure nAChR binding sites in the immunoprecipitation studies using a modification of a previously published method (Brown et al., 2007) .
Mice were chronically infused with either saline (controls), 0.25 mg/kg/h nicotine, 1.0 mg/kg/h nicotine, or 4.0 mg/kg/h nicotine (doses expressed as free base) for 10 days. After each cannula was checked for free flow, a 2-h interval between discontinuation of nicotine treatment and sacrifice was used to allow significant metabolism of nicotine (Petersen et al., 1984) . For samples to be prepared for immunoprecipitation, each mouse was killed by cervical dislocation and its brain was rapidly removed from the skull and placed on an ice-cold platform. Olfactory tubercles, hippocampus, striatum, cerebral cortex, and thalamus were dissected. Each brain region was placed in ice-cold, hypotonic buffer (14 mM NaCl, 0.22 mM KCl, 0.2 mM CaCl 2 , 0.1 mM MgSO 4 , 2.5 mM HEPES, pH 7.5) and homogenized using a glass/Teflon tissue grinder. The homogenates were subsequently centrifuged at 20,000g for 20 min. The supernatant was discarded, and the pellet was resuspended in fresh hypotonic buffer, which was again centrifuged at 20,000g for 20 min. This resuspension/centrifugation cycle was repeated three more times after which the washed pellets were stored at Ϫ70°C under fresh hypotonic buffer until assay.
On each assay day, samples for a single brain region were thawed, the pellets were resuspended in the overlying buffer, and the samples were centrifuged at 20,000g for 20 min. The resulting pellet was resuspended in PBS (composition: 136.9 mM NaCl, 2.7 mM KCl, 10.1 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 ). Particulate protein was solubilized by incubation of the sample with 2% Triton X-100 in PBS at room temperature for 1 h. After this incubation the samples were centrifuged at 20,000g for 10 min to remove insoluble material, and the supernatants were used in subsequent experiments.
Binding of [ 125 I]epibatidine to solubilized sites was measured by incubating the Triton X-100 supernatant overnight at 4°C with 200 pM [
125 I]epibatidine in a 100-l final volume of PBS containing 1% Triton X-100 . Blanks were established by including 100 M cytisine in some samples. When the incubation was complete, 100 l of 40% polyethylene glycol was added to each sample, which was then shaken for 2 min to precipitate the solubilized protein including nAChR to which [ 125 I]epibatidine was bound. Samples were diluted with 500 l of ice-cold wash buffer, and the precipitated protein was collected by filtration onto glass fiber filters that had been soaked in 0.5% polyethylenimine [two filters: top filter type B (MicroFiltration Systems); bottom filter, type A/E (Pall Life Sciences)] using an Inotech Cell Harvester (Inotech Biosystems, Rockville, MD). Samples were subsequently washed five times with ice-cold wash buffer. The washed filters were transferred to glass 12 ϫ 75-mm culture tubes and 125 I was counted at 80% efficiency on a Packard Cobra Gamma Counter (PerkinElmer Life and Analytical Sciences).
Before measuring immunoprecipitation of [ 125 I]epibatidine binding sites from multiple brain regions, experiments were conducted to determine the mAb affinity and extent of immunoprecipitation achieved with mAb 299 and mAb 270. Precipitation curves for the concentration dependence of mAb 299 and mAb 270 were constructed using hippocampal extracts prepared from mice treated with saline or 4.0 mg/kg/h nicotine. For mAb 299, the concentrations that achieved half-maximal specific immunoprecipitation were 0.02 Ϯ 0.01 and 0.03 Ϯ 0.01 g/ml and total specific immunocapture Chronic Nicotine and Brain nAChRs 189 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org was 20.9 Ϯ 1.4 and 30.3 Ϯ 1.1 fmol/mg protein for saline-and nicotine-treated mice, respectively. For mAb 270, the concentrations that achieved half-maximal specific immunoprecipitation were 0.62 Ϯ 0.21 and 0.97 Ϯ 0.21 g/ml and total specific immunocapture was 22.6 Ϯ 2.1 and 34.8 Ϯ 2.2 fmol/mg protein for saline-and nicotine-treated mice, respectively. For both mAbs maximal specific immunoprecipitation revealed a significant difference between saline-and nicotine-treated mice (for mAb 299, t 8 ϭ 5.32, p Ͻ 0.05; for mAb 270, t 8 ϭ 3.98, p Ͻ 0.05), but no significant difference in antibody affinity was detected between the two groups.
Immunoprecipitation of ␤2*-nAChR with mAb 270 and ␣4* nAChRs with mAb 299, which were raised in rats, was achieved using a rabbit antibody directed against rat IgG to form an insoluble protein precipitate from nAChRs labeled with 125 I-epibatidine. Final mAb concentrations were 5 g/ml mAb 270 or 1 g/ml mAb 299. These concentrations had been determined to be saturating from experiments designed to determine the affinity of the antibodies using hippocampal tissue of mice treated with saline or 4.0 mg/kg/h nicotine. Solubilized protein was incubated in 100 l of buffer containing 200 pM 125 I-epibatidine, 1% Triton X-100 PBS, and 3% normal rat serum in addition to the appropriate mAb. Nonspecific 125 I-epibatidine labeling was determined by including 100 M cytisine in the incubation. Samples were incubated overnight at 4°C. After the overnight incubation, the insoluble protein complex was formed by the addition of 50 l of rabbit-anti-rat IgG (1 mg/ml in PBS), and incubation at 4°C for 60 min. Immediately before capture, the samples were diluted with 1 ml of ice-cold 1% Triton X-100 in PBS to reduce nonspecific capture of labeled nAChRs. The precipitates were isolated by filtration onto 0.5% polyethylenimine-soaked glass fiber filters (top filter type B, bottom filter type A/E) and washed three times with ice-cold PBS. The washed filters were transferred to glass 12 ϫ 75-mm culture tubes, and 125 I was counted at 80% efficiency on a Packard Cobra Gamma Counter.
Protein. Protein was measured using the method of Lowry et al. (1951) .
Statistical Analyses. The SPSS statistical package (SPSS Inc., Chicago, IL) was used for all analyses. One-way ANOVAs were used to examine the effects of nicotine treatment on binding site density for each ligand in each brain region. Linear regression analysis was used to compare the signal intensity in the various brain regions for mAb 270 and mAb 299 to that of A85380 at each infusion dose. One-way ANOVAs were also used to examine the effect of nicotine treatment on 125 I-epibatidine binding sites in tissue homogenates, Triton X-100-solubilized sites, and solubilized sites precipitated by either mAb 270 or mAb 299. No systematic deviation of the data points from the regression line was noted. Such a relationship is not unexpected inasmuch as I-A85380 has been identified as a ␤2*-nAChR-selective ligand (Mukhin et al., 2000) .
Results
Binding
The scattergram in Fig. 1 ]mAb 299 has been calculated omitting the points for brain regions for which nAChR other than ␣4␤2*-nAChR have been identified (Whiteaker et al., 2006) . VLG, ventrolateral geniculate nucleus; mHab, medial habenula; SC, superior colliculus; sg, superficial gray; DLG, dorsolateral geniculate nucleus; IPN, interpeduncular nucleus. ferior colliculus, and several midbrain and hindbrain nuclei. Maximal increases ranged from 40% in the deep layers of superior colliculus to 144% in the accessory olfactory nucleus.
No significant differences in [ 125 I]A85380 binding were observed in 16 of the 38 regions quantitated. These regions included anteriodorsal, laterodorsal, mediodorsal, and ventraolateral thalamic nuclei, dosolateral, ventrolateral, and medial geniculate nuclei, most parts of the basal ganglion including caudate putamen, nucleus accumbens, substantia nigra pars compacta and ventral tegmental area (with the olfactory tubercle being an exception), and the medial habenula and interpeducnular nucleus. Although changes in these brain regions were not significant, binding site density tended to show modest increases (9% in interpeduncular nucleus to 40% in nucleus accumbens).
The differential effect of chronic nicotine treatment on the up-regulation of nicotinic binding sites in mouse brain regions observed here is comparable with that seen with other nicotinic cholinergic ligands in mice (Marks et al., 1983 (Marks et al., , 2004 Pauly et al., 1991) and rats (Sanderson et al., 1993; Nguyen et al., 2003 Figure 3 illustrates the effects of chronic nicotine treatment at the level of the thalamus and medial habenula (approximately Ϫ1.6 mm Bregma). Saturable increases in overall binding are observed in the outer and inner cortical layers and hypothalamus, whereas no significant effect of chronic nicotine treatment was noted in mediodorsal thalamus. In each of these regions, the effects of chronic nicotine treatment on [
125 I]A85380, [ 125 I]mAb 299, and mAb 270 binding are similar and these responses do not differ markedly from the curves describing the average dose dependence. Figure 4 illustrates the effects of chronic nicotine treatment at the level of the superior colliculus and the interpeduncular nucleus (approximately Ϫ2.6 mm Bregma). Saturable increases in overall binding site densities were noted for periaquiductal gray and deep mesencephalic nucleus, with a less robust change observed in the superficial gray area of the superior colliculus. No significant effect of nicotine treatment was observed for any ligand in the interpeduncular nucleus. The effect of chronic nicotine treatment on [ 125 I]A85380, [
125 I]mAb 299, and mAb 270 binding in periaquiductal gray, deep mesencephalic nucleus, and interpeduncular nucleus is similar and does not differ markedly from the average nicotine dose dependence in these regions. In contrast to the responses in these three regions, but similar to the patterns observed for caudate putamen, nucleus accumbens, and olfactory tubercle (Fig. 2) 125 I]mAb 270, respectively. However, the slopes of the scattergrams relating ligand binding to subunit density differ significantly from unity. This result may merely be a consequence of the differences in assay conditions such as the fact that mAb concentrations are subsaturating whereas [
125 I]A85380 concentration is saturating, the specific activity of functional mAbs may have been overestimated, and lower tissue and cell membrane permeability of mAbs occurred. However, the difference may reflect some inability of the mAb to recognize all mouse ␣4-nAChR or ␤2-nAChR subunits. To address this possibility, the ability of mAb 299 and mAb 270 to immunoprecipitate detergent-solubilized ligand binding sites in control and nicotine-treated mouse brain regions was assessed.
Immunoprecipitation was examined in cortical, hippocampal, striatal, and thalamic homogenates of mice chronically treated with 0 (control), 0.25, 1.0, or 4.0 mg/kg/h nicotine. These regions and nicotine treatment doses were chosen to include brain areas that show relatively robust responses to nicotine (cortex and hippocampus) or show little response to nicotine (thalamus). Striatum and olfactory tubercles were also included because these brain regions contain non-␣4␤2-nAChR binding sites. Table 4 presents these data.
Precipitation of [ 125 I]epibatidine binding sites by mAb 270 in the saline-treated mice was virtually quantitative in four of the brain regions (mean Ϯ S.E.M. of the Triton X-100-solubilized [
125 I]epibatidine binding sites: 99 Ϯ 12% in cortex, 116 Ϯ 8% in hippocampus, 98 Ϯ 5% in thalamus, and 100 Ϯ 19% in striatum), but was less complete in olfactory tubercles (67 Ϯ 5%). mAb 299 was less efficient in precipitating these sites (mean Ϯ S.E.M. of the Triton X-100-solubilized [
125 I]epibatidine binding sites: 75 Ϯ 10% in cortex, 90 Ϯ 6% in hippocampus, 86 Ϯ 4% in thalamus, 57 Ϯ 14% in striatum, and 57 Ϯ 4% in olfactory tubercles). 125 I]epibatidine binding sites precipitated by PEG, mAb 270, and mAb 299 in cortex (increases), hippocampus (increases), and thalamus (no changes) were very similar in both the extent of increase and the nicotine dependence of the response. In contrast, the relative changes in response to nicotine of the [
125 I]epibatidine binding sites precipitated by PEG, mAb 270, and mAb 299 in olfactory tubercles and striatum differed. In olfactory tubercles, the pattern of increase in [ 125 I]epibatidine binding sites precipitated by PEG, mAb 270, and mAb 299 was similar, but the relative number of sites precipitated by the two antibodies was slightly higher than the relative increase in the total, PEG-precipitable counts. In striatum, the pattern and relative increase in [
125 I]epibatidine binding sites precipitated by PEG and mAb 299 were similar. Relatively fewer sites were precipitated by mAb 270 after treatment with 0.25 or 1.0 mg/kg/h nicotine, but precipitation of sites by mAb 270 in striatum of mice treated with 4.0 mg/kg/h nicotine was similar to that for PEG and mAb 299.
Discussion
We have demonstrated, using an extensive analysis of region-specific up-regulation of nAChRs in mouse brain, that chronic nicotine treatment elicits corresponding increases in ␤2*-nAChR binding sites and ␣4-nAChR and ␤2-nAChR subunit proteins measured with mAb binding . These results strongly support the hypothesis that nicotine-induced up- These results are expected from experiments with cell cultures that show that nicotine exposure increases the assembly of ␣4␤2-nAChR from subunit pools and decreases the rate of turnover of mature nAChRs on the cell surface (Kuryatov et al., 2005; Sallette et al., 2005; Lester et al., 2009) .
The region-selective changes in the binding of [ 125 I]A85380, which is a ␤2*-nAChR subtype-selective ligand (Mukhin et al., 2000) , are consistent with previous autoradiographic studies using other ligands that bind to ␣4␤2*-nAChR (Pauly et al., 1991; Sparks and Pauly, 1999; Nguyen et al., 2003 (Pauly et al., 1991; Sparks and Pauly, 1999; Nguyen et al., 2003) .
Most of the binding sites that increase after chronic nicotine treatment can be immunoprecipitated by antibodies to either the ␣4-or ␤2-nAChR subunit (Flores et al., 1992; Mao et al., 2008; Moretti et al., 2010) consistent with the observation that nAChRs remaining in ␤2 knockout mice are resistant to the effects of chronic nicotine treatment (McCallum et al., 2006) . Although immunoprecipitation experiments provide important information about the subunit compositions of nAChR subtypes and illustrate regional differences in nAChR regulation, they lack the anatomical resolution achieved with autoradiography or immunocytochemistry. Unfortunately, standard immunocytochemical methods with antibodies directed at nAChR subunits have been problematic (Jones and Wonnacott, 2005; Moser et al., 2007) . However, [ 125 I]mAb 270, which binds to the ␤2-nAChR subunit, labels nAChR in unfixed rodent brain with regional distributions paralleling those of high-affinity agonist binding sites (Swanson et al., 1987 (Whiteaker et al., 2006) . This study demonstrated that both mAbs recognize assembled nAChR in brain sections rather than individual subunit proteins because of the loss of labeling after deletion of either the ␣4 or ␤2 gene. However, both mAbs recognize unassembled or partially as- ]mAb 270 binding site densities were observed for each nicotine dose. This result supports the conclusion that the increases in ligand binding density reflect increases in nAChR subunit protein. This conclusion is consistent with the observations that chronic nicotine treatment increases the expression of fluorescently labeled ␣4-nAChR subunit protein (Nashmi et al., 2007) Kellar, 2004; Perry et al., 2007; Perez et al., 2008; Moretti et al., 2010) . Thus, the relatively smaller in- . Technical differences between ligand binding and antibody labeling could account for these differences, including, but not limited to, the use of nonsaturating mAb concentrations (this accounts for approximately a factor of two of the differences), differences in penetration of the probes into the tissue (the relatively small and membrane-permeable [
125 I]A85380 is more likely to penetrate fully into the sections than are the mAbs that are nearly 1000-fold larger and membrane impermeable), and/or inaccurate definition of specific activity of the functional mAbs owing to possible degradation of the mAb between its synthesis and use in experiment.
Immunoprecipitation 125 I]mAb 270 (␤2 subunit protein), in both brain regions that respond to chronic nicotine treatment and those that are resistant to the druginduced increase in ligand binding. Immunoprecipitation studies confirm that mAb 270 and mAb 299 recognize ligand binding sites in samples prepared from several brain regions of mice treated with nicotine. Taken together, these results demonstrate that the increases in ␣4␤2*-nAChR binding sites after chronic nicotine treatment of mice result from an increase in the number of nAChRs containing ␣4 and ␤2 subunit proteins. ]epibatidine, and solubilized binding sites were collected by incubation with 20% PEG (F) to quantitatively precipitate the binding sites, with mAb 299 followed by rabbit anti-rat serum (Ⅺ) to immunoprecipitate sites containing the ␣4-nAChR subunit or mAb 270 followed by rabbit anti-rat serum (‚) to immunoprecipitate sites containing the ␤2-nAChR subunit. Each data point represents the mean Ϯ S.E.M. of five to six individual mice treated with one of the four nicotine doses. The data have been normalized to the binding measured for saline-treated mice. The curves are the nonlinear least-squares curve fits for the PEG-precipitated counts.
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